Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308: 147–156.

Published: 9th May 2013

Authors: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC et al. et al.


Some 428 patients were randomized to one of two chemotherapy regimens or a control group. Although the subsequent mortality rate was similar in each group, multivariable analysis adjusting for prognostic factors suggested a significant survival benefit from adjuvant chemotherapy: hazard ratio 0.75, 95 per cent confidence interval 0.57 to 0.98, P=0.03.

Pubmed Link

Your comments